Now showing items 1-6 of 6

• #### A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients ﻿

(2015-12-16)
Abstract Background Personalized therapy considering clinical and genetic patient characteristics will further improve breast cancer survival. Two widely used treatments, ...
• #### Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry ﻿

(Springer, 2016-04-06)
Purpose Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of breast cancer. It is unclear, however, whether this association is due to shared genetic factors. Methods We constructed a ...
• #### Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation ﻿

(Nature Publishing Group, 2016-04-07)
Although genome-wide association studies have identified over 100 risk loci that explain ~33% of familial risk for prostate cancer (PrCa), their functional effects on risk remain largely unknown. Here we use genotype data ...
• #### Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent ﻿

(Public Library of Science, 2016-08-23)
$\textbf{Background}$ Observational epidemiological studies have shown that high body mass index (BMI) is associated with a reduced risk of breast cancer in premenopausal women but an increased risk in postmenopausal ...
• #### Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer ﻿

(Impact Journals, 2016-01-31)
Women with epithelial ovarian cancer (EOC) are usually treated with platinum/taxane therapy after cytoreductive surgery but there is considerable inter-individual variation in response. To identify germline single-nucleotide ...
• #### PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS ﻿

(BMJ Publishing Group, 2016-09-05)
Background The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are ...